BioCentury
ARTICLE | Clinical News

Idec reports Phase III Zevalin NHL data

December 5, 2000 8:00 AM UTC

In an open-label Phase III study of 54 patients with non-Hodgkin's lymphoma (NHL) who had failed to respond to or progressed following treatment with IDPH's Rituxan rituximab, IDPH said that its Zeval...